~~<i id='47C594D23F'><strike id='47C594D23F'><tt id='47C594D23F'><pre id='47C594D23F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：Wikipedia 2025-09-06 06:16:49 - browse：93

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Why don't Americans have at

leisure time

entertainment

hotspot

entertainment

focus

explore

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

WSS

Latigo launches with $135 million for Vertex

Pregnant women don't need prenatal multivitamins, study concludes

AMAs digital advisors table RPM coding reform proposal, again

Study gives hint on South Asians’ higher risk of cardiovascular disease

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Harvard's David Sinclair gets blowback over aging

explore

hotspot

leisure time

Peter Hotez and the public health issue of online harassment

Ebola vaccine can save some who are already sick, per new study

Hepatitis C has a cure — but many Americans still lack access to it

Biden's 'march

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: BridgeBio, Akero, and human embryo models

Moonlake's readout produced a cash windfall. Risks remain

Ozempic has benefits for kidney disease as well as diabetes

Hepatitis C has a cure — but many Americans still lack access to it

The untold story of TV’s first prescription drug ad

entertainment

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Congress must protect the remaining independent doctors

Latigo launches with $135 million for Vertex

Microsoft's Peter Lee: Generative AI could help doctors be more human

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Study gives hint on South Asians’ higher risk of cardiovascular disease

hotspot

entertainment

focus

explore